Tocopherol is a Novel Treatment for Cancer Related Mucositis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present protocol is an attempt to prevent/treat mucositis in highly susceptible patients subjected to maximally tolerated doses of subsequently-myeloablative or myeloablative doses of chemoradiotherapy supported by autologous or allogeneic stem cell transplantation at the Department of Bone Marrow Transplantation. Mucositis is a major problem in the management of transplant recipients which subjects the patients to the risk of sepsis, need for parenteral nutrition and need of narcotics. We are planning a 2 arm study, comparing 2 safe vitamin E based formulations with placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vitamin E to Prevent Mucositis in Children With Cancer

NCT00311116

Cancer

COMPLETED PHASE2/PHASE3

Oral Selenium Therapy for the Prevention of Mucositis

NCT01432873

Mucositis Hematopoietic Stem Cell Transplantation

UNKNOWN PHASE1/PHASE2

Prevention of Oral Mucositis After Using Oral Topical Vitamin E Versus Voriconazole and Levofloxacin in Pediatric Cancer Patients Receiving Chemotherapy

NCT03613389

Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy

UNKNOWN NA

Oral Zinc Therapy for the Prevention of Mucositis

NCT00449592

Mucositis

COMPLETED PHASE4

Efficacy of Propolis in the Prevention of Oral Mucositis

NCT05250661

Oral Mucositis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oral Mucositis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tocopherol

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and non-pregnant and non-lactating females, 18 years of age or older at the time of screening, who are to receive myeloablative agonists with or without total body irradiation (TBI) in preparation for either allogeneic or autologous HSCT. Patients who are to be hospitalized and are expected to remain hospitalized until marrow recovery.
* Karnofsky performance status of 60 or greater or ECOG performance status of 2 or less.
* Normal dental examination as assessed by the investigator.

Exclusion Criteria

* Clinically significant acute and active oral cavity infection.
* Patients taking any investigational or other non-approved oral therapy for oral mucositis.
* Known hypersensitivity to Vitamin E.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No